Berlin, 21st April 2026. The medtech company Magnosco has developed idea® (interactive dermatoscopic examination assistant), a worldwide unique AI-powered software solution for skin cancer diagnosis. It has been proven to increase the diagnostic accuracy of specialists by almost 60 percent, particularly when assessing skin lesions that are difficult to evaluate.

Decision-making logic instead of a black box

idea® is an interactive decision-making tool for dermatologists. Many existing AI solutions act as a ‘black box’, producing an opaque risk score. idea®, however, makes the diagnostically relevant dermatoscopic structures, including attributes such as colours, symmetry and pattern characteristics, directly visible and generates a list of features for the lesion based on established dermatoscopic textbook knowledge. It provides only interpretable content and visualises it.

Clinician-in-the-Loop

Doctors can then confirm, correct or add to the features. This allows for medical interaction even before a transparent diagnostic classification is provided by the AI. This ‘Clinician-in-the-Loop’ principle explicitly integrates medical knowledge and makes the decision traceable and explainable. The final diagnosis remains with the doctor. In this way, Magnosco builds trust through the transparency of the diagnostic process.

International Expert Assessment

A two-phase, international reader study involving 16 medical participants trained in dermatoscopy investigated how idea® affects diagnoses and treatment decisions. The study demonstrates a measurable benefit precisely where it matters most clinically: in difficult, error-prone or unclear cases. Diagnostic accuracy more than doubled in conjunction with idea®, and treatment decisions improved by over 35 percent. Furthermore, idea® received an overall positive rating for its suitability for clinical workflows.¹

The dimensions of skin cancer diagnostics

In addition to the software, Magnosco has developed Magnos®, a certified digital dermatoscope with high colour fidelity, which is used in combination with idea®. The aim is to achieve standardised image quality, thus reducing performance fluctuations caused by different cameras, lighting conditions or device changes – a common problem in the real-world implementation of vision AI. The system’s outstanding usability was recognised in 2025 with the internationally renowned IF Design Award. The dermatoscope has been marketed primarily in the German market for over a year.

CE certification for idea® as a Class IIa medical device is imminent – a crucial milestone in the history of the medtech company.

This will be followed by expansion into the German market and entry into international markets, with the aim of establishing this innovative solution across different countries and healthcare systems.

Skin cancer is a global problem, and efficient diagnostics can significantly reduce risks for those affected through early detection, provided rapid treatment is possible. AI and digitalisation can make a decisive contribution in this regard

¹L. Szyc et al. – Does interactive dermatoscopic AI-aided patterns detection and visualization improve clinical decisions in dermatoscopy? Results from a two‑phase reader study. – in preparation